Home / Market News / $MSOS
benzinga Corporate Catalyst Impact 85/100 ● negative

Shares of cannabis-related companies are trading lower following a report suggesting that a Drug Enforcement Administration judge is pausing proceedings in an ongoing hearing on the Trump administration’s marijuana rescheduling proposal.

Sep 30, 2026, 3:44 PM UTC · Primary ticker $MSOS

The pause in the DEA's marijuana rescheduling hearing introduces significant uncertainty for cannabis companies, as the prospect of federal reform is a major driver of their valuations. This delay dampens investor sentiment, leading to a sell-off in the sector due to prolonged regulatory ambiguity.

This news is a significant negative catalyst for the cannabis sector. The potential rescheduling of marijuana from Schedule I to Schedule III under federal law is a key driver for the industry, promising reduced regulatory burdens, increased access to banking, and potential for broader market expansion. A pause in these proceedings introduces prolonged uncertainty, which typically leads to investor apprehension and selling pressure. Companies like Canopy Growth (CGC) and Tilray (TLRY), which have significant exposure to the US market or are poised to benefit from federal reform, will likely see their shares decline. The broader cannabis ETF (MSOS) will also be negatively impacted. Traders should anticipate continued volatility and potential downward pressure on cannabis stocks until there is clearer guidance on the rescheduling process.

$CGC negative Leading cannabis producer, highly sensitive to regulatory news
$TLRY negative Major cannabis player, impacted by rescheduling delays
$SNDL negative Cannabis and liquor retailer, affected by federal policy
$MSOS negative ETF tracking US cannabis companies, direct exposure to sector sentiment
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.